Chemo Tied to Long-Lasting Physical Health Decline for Breast Cancer Survivors
By Elana Gotkine HealthDay Reporter
WEDNESDAY, March 5, 2025 -- Breast cancer (BC) survivors who receive chemotherapy may experience greater physical health decline than those who receive endocrine therapy alone, according to a study published online Feb. 28 in JAMA Network Open.
Clara Bodelon, Ph.D., from the American Cancer Society in Atlanta, and colleagues conducted a prospective cohort study of participants in 35 states, the District of Columbia, and Puerto Rico between 2006 and 2013 to examine physical health decline in BC survivors who received chemotherapy or endocrine therapy compared with age-matched women without cancer. Data were included for 2,566 women diagnosed with BC and 12,826 women without cancer.
Of the women with BC, 47.7, 10.8, and 24.7 percent received endocrine therapy, chemotherapy, and both, respectively. The researchers found greater physical health decline within two years of diagnosis for BC survivors receiving endocrine therapy, chemotherapy, or both (β = −1.12, −3.13, and −3.26, respectively). The decline among endocrine therapy users was only seen in women receiving aromatase inhibitors. More than two years after diagnosis, only women who received chemotherapy experienced a decline in physical health.
"Understanding the survivorship care needs and management of late effects in BC survivors is critical," the authors write. "Continued efforts are needed to understand the specific survivorship care needs of BC survivors and improve their long-term quality of life."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Dietary Patterns Influence Development of Overactive Bladder
FRIDAY, June 20, 2025 -- Dietary patterns influence the development of overactive bladder (OAB), according to a study published online May 12 in Frontiers of Nutrition. Yiming...
Nearly Half With Early-Stage Breast Cancer Extend Endocrine Therapy Beyond Five Years
FRIDAY, June 20, 2025 -- Nearly 40 percent of women with stage I breast cancer and two-thirds with stage II decide to extend endocrine therapy, according to a study published...
Mismatch Repair Germline Pathogenic Variants Could Predispose to Uveal Melanoma
FRIDAY, June 20, 2025 -- Mismatch repair (MMR) germline alterations are enriched among patients with uveal melanoma (UM), according to a study published online June 18 in JAMA...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.